Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study.
Adam RosenbergCatelyn CashionFariya AliHarini HaranRaaj K BiswasVivien M Y ChenHelen CrowtherJennifer CurnowElyssa DeakinChee Wee TanYi Ling TanAndrew VanlintChristopher M WardRobert J BirdDavid J RabboliniPublished in: Research and practice in thrombosis and haemostasis (2022)
A wide range of "second-line" agents were used across centers with variable response rates and side effect profiles. Findings suggest greater effectiveness of rituximab and TPO-A, supporting their use earlier in the treatment course of patients with ITP across Australia.